These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27259384)

  • 1. Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal.
    Herdeiro MT; Soares S; Silva T; Roque F; Figueiras A
    Fundam Clin Pharmacol; 2016 Oct; 30(5):440-9. PubMed ID: 27259384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
    Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
    Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
    Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
    Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
    Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM; Taylor TN; Jaber LA
    Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone and implications for pharmacovigilance.
    Kazi D
    BMJ; 2007 Jun; 334(7606):1233-4. PubMed ID: 17569897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical consequences of disseminating the rosiglitazone FDA safety warning.
    Orrico KB; Lin JK; Wei A; Yue H
    Am J Manag Care; 2010 May; 16(5):e111-6. PubMed ID: 20455636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone prior authorization safety policy: a cohort study.
    Starner CI; Fenrick B; Coleman J; Wickersham P; Gleason PP
    J Manag Care Pharm; 2012 Apr; 18(3):225-33. PubMed ID: 22468731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
    Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E
    Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety Alerts: An Observational Study in Portugal.
    Soares S; Roque F; Teixeira Rodrigues A; Figueiras A; Herdeiro MT
    Clin Ther; 2015 Sep; 37(9):2122-8. PubMed ID: 26256430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.
    Niyomnaitham S; Page A; La Caze A; Whitfield K; Smith AJ
    BMC Health Serv Res; 2014 Apr; 14():151. PubMed ID: 24708579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.
    Leal I; Romio SA; Schuemie M; Oteri A; Sturkenboom M; Trifirò G
    Br J Clin Pharmacol; 2013 Mar; 75(3):861-8. PubMed ID: 22845019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
    Califf RM; Kramer JM
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):782-6. PubMed ID: 18655016
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM; Le L; Zhang S; Harada AS
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone: what went wrong?
    Cohen D
    BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long Avandia endgame.
    Mullard A
    Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.